⏳ Fetching live dividend data...
Home › Calculator › NAVB Dividend Calculator 2026
Navidea Biopharmaceuticals, Inc. · OTC
Price: $0.00 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
NAVB is not a dividend-focused stock
NAVB pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Navidea Biopharmaceuticals, Inc. (NAVB) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm dedicated to creating and marketing highly specific diagnostic tools that leverage the immune system, as well as therapeutic agents also based on immune principles. Its operations are divided into two primary divisions: Diagnostic Substances and Therapeutic Development Programs. Central to its efforts is the Manocept platform, designed to selectively bind to the CD206 mannose receptor found on activated macrophages. This innovative platform enables various diagnostic techniques, such as single photon emission computed tomography (SPECT), positron emission tomography (PET), gamma-scanning, and intra-operative or optical-fluorescence detection. Additionally, it facilitates the targeted delivery of therapeutic agents to macrophages, addressing a spectrum of immune- and inflammation-related conditions. The company's pipeline includes several key candidates for rheumatoid arthritis (RA). NAV3-31 has successfully concluded Phase IIb clinical trials, where its imaging repeatability, reproducibility, and stability were assessed. These trials also investigated the potential of Tc99m tilmanocept imaging to guide anti-tumor necrosis factor alpha therapy for individuals suffering from moderate to severe RA. Furthermore, NAV3-35 is currently undergoing a Phase IIb clinical trial for RA imaging, while NAV3-33 is advancing through Phase III clinical trials for RA. Another compound, NAV3-32, is in Phase 2b trials, focusing on RA-affected joints. Beyond RA, Navidea is exploring the utility of Tc99m tilmanocept for various other applications, including cardiovascular conditions, Kaposi's sarcoma, tuberculosis, and additional immunotherapeutic uses. Originally established as Neoprobe Corporation, the company adopted its current name, Navidea Biopharmaceuticals, Inc., in January 2012. Founded in 1983, its corporate headquarters are located in Dublin, Ohio.
No. Navidea Biopharmaceuticals, Inc. (NAVB) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. NAVB has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open NAVB position with:
Real after-tax yield depends on where you live and how you hold NAVB.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
NAVB pays quarterly — 4 times per year. Ex-div: —.
How NAVB compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for NAVB sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2021-12-27 | 100,000 | $1.08 | $108.0K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Compare NAVB with peers: NAVB vs ACORQ · NAVB vs CRXM · NAVB vs GDBYF
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the NAVB dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Navidea Biopharmaceuticals, Inc. (NAVB) is currently trading at $0.00, trading near its 52-week low. It does not currently pay a regular dividend.
Navidea Biopharmaceuticals, Inc. (NAVB) is a healthcare stock trading at $0.00. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only — not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever